Compound Guide
KPV Peptide Research — α-MSH Tripeptide, NF-κB Inhibition & Gut Inflammation
Editorial Standards
Avera Refined Wellness holds its research journal content to a standard requiring specific research claims to reference published, peer-reviewed sources — not general assertions. We are in the process of auditing and updating existing journal content to consistently meet this standard.
KPV peptide: α-MSH tripeptide inhibiting NF-κB via PepT1 transporter. Anti-inflammatory effects in two murine colitis models. Gastroenterology 2008 citation.
All products are supplied strictly for in-vitro laboratory research use only by qualified professionals. Not for human consumption. Not intended to diagnose, treat, cure, or prevent any disease.
KPV is a tripeptide (Lys-Pro-Val) corresponding to residues 11–13 of alpha-melanocyte-stimulating hormone (α-MSH). The three C-terminal amino acids retain much of α-MSH's anti-inflammatory activity while losing its pigmentary effects. KPV's mechanism is intracellular: it enters cells via the PepT1 nutrient transporter and directly inhibits NF-κB activation in the nucleus — not via melanocortin receptors.
Mechanism: PepT1-Mediated NF-κB Inhibition
The mechanistic understanding summarized here is established by the Dalmasso G et al. work cited below: KPV is transported into intestinal and epithelial cells via PepT1, and once intracellular it inhibits NF-κB — the master regulator of TNF-α, IL-1β, and IL-6 synthesis. Dalmasso G et al. (Gastroenterology. 2008;134(1):166–178) demonstrated that KPV retains its anti-inflammatory activity in MC1R-knockout mice, confirming a PepT1-mediated intracellular mechanism rather than signaling through melanocortin receptors (MCR).
Inflammatory Bowel Disease Models
Kannengiesser K et al. (Inflamm Bowel Dis. 2008;14(3):324–331) demonstrated significant anti-inflammatory effects in DSS-induced colitis and CD45RBhi transfer colitis. In the DSS model, KPV-treated animals showed earlier recovery, greater body weight regain, and reduced inflammatory infiltrates on histology. In the most severe protocol, KPV rescued all treated animals from death versus significant mortality in untreated controls.
Key References
- Dalmasso G, et al. PepT1-mediated tripeptide KPV uptake reduces intestinal inflammation. Gastroenterology. 2008;134(1):166–178.
- Kannengiesser K, et al. KPV has anti-inflammatory potential in murine IBD models. Inflamm Bowel Dis. 2008;14(3):324–331.
For educational and research reference only. KPV is supplied for in-vitro laboratory research use only. Not for human consumption.
Research Disclaimer: All content published in the Avera Research Journal is provided for informational and scientific discussion purposes only. It does not constitute medical advice, treatment guidance, or a recommendation for human use of any compound. All Avera products are supplied exclusively for in-vitro laboratory research by qualified professionals. Not FDA-evaluated. Not for human consumption.
This article is for informational and research purposes only. All compounds referenced are sold strictly for in-vitro laboratory research use and are not intended for human consumption, veterinary use, or clinical/diagnostic procedures. These statements have not been evaluated by the FDA. Avera Refined Wellness is a subsidiary of RDS 412 LLC.
Related Research